Semaglutide for Weight Loss Also Significantly Reduced Alcohol Use Disorder Symptoms in Six Patients

The researchers conducted a retrospective chart review to identify patients prescribed semaglutide for weight loss who also had positive AUD screenings (AUDIT score > 8) before starting semaglutide. Six patients meeting these criteria were identified. Their AUDIT scores before and after semaglutide therapy were compared using a paired t-test.

Alcohol use disorder is a leading cause of preventable death worldwide, yet only three FDA-approved drugs exist to treat it. If semaglutide and other GLP-1 receptor agonists can genuinely reduce alcohol cravings and consumption — as both animal studies and now this human case series suggest — it could open an entirely new treatment avenue for a condition that remains stubbornly difficult to manage.

This case series is part of a growing wave of clinical observations suggesting GLP-1 receptor agonists like semaglutide may have effects well beyond glucose control and weight loss. Reports of reduced cravings for alcohol, nicotine, and other substances have emerged alongside the massive adoption of these drugs. Understanding whether GLP-1 signaling directly modulates reward pathways could reshape addiction treatment — but rigorous randomized controlled trials are needed to move beyond anecdote.

This is a case series of only 6 patients with no control group, no randomization, and no blinding. The retrospective design means the findings could be influenced by confounding factors — for example, patients may have changed drinking behavior due to nausea from semaglutide, weight loss motivation, or other lifestyle changes. The AUDIT score improvement could partially reflect reduced caloric intake from alcohol rather than reduced craving specifically. Much larger randomized controlled trials are needed.